Zimmer Biomet Doubling Down on Innovation During COVID

While the company’s orthopedic revenues declined in the high single-digits in 1Q20, Zimmer Biomet’s balance sheet and cost containment measures will allow it to aggressively pursue key R&D initiatives.

Integra LifeSciences Anticipates Market Recovery in 4Q20

The company’s orthopedic business declined in mid-single digits for 1Q20, with a precipitous -80% decline in April. However, Integra expects the market to right itself by year-end.

Orthofix Procedure Volume Down -60% in April Due to COVID-19

The company’s sales declined in the mid-single digits in 1Q20, but included a few bright spots like continuing adoption of the M6-C artificial disc.

ATEC Spine Bullish on Growth Prospects Despite COVID

The company’s late-2019 growth momentum continued for most of 1Q20, resulting in nearly 22.6% growth. ATEC is confident the spine market will be one of the first to rebound from COVID-19.

DJO’s Share-Taking Momentum Undercut by COVID-19

The company was on pace to deliver double-digit growth in 1Q20 before COVID-related surgical delays, and procedures were down roughly 90% in April.

Anika Top Line Growth Fueled by Parcus and Arthosurface Acquisitions

The company’s 1Q20 growth amid COVID-19 was fueled by $6.8 million in sales from Parcus and Arthosurface, in addition to continuing purchase orders of legacy viscosupplements.

OrthoPediatrics Hits Double-Digit Growth in 1Q20 Despite COVID Downturn

The company rode early 1Q momentum to grow in the low double-digits despite COVID-related procedure deferrals, and has seen signs of incremental recovery in May.

Globus Expects to Emerge from COVID-19 in Stronger Position

The company managed to drive single-digit growth despite the late-March impact of COVID and expects to be well-positioned to benefit from the inevitable market consolidation occurring due to the pandemic.

NuVasive in Strong Position to Weather the COVID-19 Storm

NuVasive suffered modest impact from COVID-19 in 1Q20 and expects severe reductions in 2Q. However, the company is using its strong cash position to push forward with product development.

Vericel Confident in Near-Term MACI Recovery

Vericel’s MACI revenue grew 22% in 1Q20 despite mid-March disruptions from COVID-19. The company believes it has passed the market low point and remains confident it will recoup most lost procedures.